|
| Press Releases |
|
 |
|
| Tuesday, March 28, 2017 |
|
|
Frost & Sullivan獨立行業報告將PromarkerD確定為糖尿病腎臟疾病的領先診斷試驗 |
| 依照本月發布的獨立Frost & Sullivan報告，Proteomics International Laboratories Ltd (PILL,ASX:PIQ)成為糖尿病腎臟疾病的預測診斷的領導者。 more info >> |
|
|
Frost & Sullivan独立行业报告将PromarkerD确定为糖尿病肾脏疾病的领先诊断试验 |
| 依照本月发布的独立Frost & Sullivan报告，Proteomics International Laboratories Ltd (ASX:PIQ)(PILL) 成为糖尿病肾脏疾病的预测诊断的领导者。 more info >> |
|
| Thursday, March 23, 2017 |
|
|
PromarkerD Predictive Test for Diabetic Kidney Disease to Roll-out in Asia |
| Proteomics International Laboratories Ltd ('PILL'; ASX: PIQ), a world leader in biomarker discovery in multiple project areas, is advancing deals this week in Singapore, Hong Kong and Shanghai for the Asia Pacific commercialization of PromarkerD. more info >> |
|
| Wednesday, March 22, 2017 |
|
|
PromarkerD糖尿病腎臟疾病預測試驗在亞洲推出 |
全球糖尿病腎臟疾病的預測診斷領導者Proteomics International Laboratories Ltd (‘PILL’; ASX:PIQ) 將於本週在新加坡，香港和上海商業化突破性的預測試驗PromarkerD，藉此打開亞洲市場。 PILL的PromarkerD已在中國、新加坡、俄羅斯、澳大利亞和美國獲得專利。
more info >> |
|
|
PromarkerD糖尿病肾脏疾病预测试验在亚洲推出 |
| 全球糖尿病肾脏疾病的预测诊断领导者Proteomics International Laboratories Ltd (‘PILL’; ASX:PIQ) 将于本周在新加坡和中国商业化突破性的预测试验PromarkerD，借此打开亚洲市场。PILL的PromarkerD已在中国、新加坡、俄罗斯、澳大利亚和美国获得专利。 more info >> |
|
|
PromarkerD Predictive Diagnostics for DKD to Roll-out in Asia |
| Proteomics International Laboratories Ltd ('PILL'; ASX: PIQ), a world leader in biomarker discovery in multiple project areas, will advance deals in Singapore, Hong Kong and Shanghai this week for the commercialization of PromarkerD, its ground-breaking predictive test, in Asia Pacific markets. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Mr Liu Xiaojun, on behalf of Fufeng Group, has fully completed the acquisition of Viva World Trade, Inc.
Feb 7, 2026 05:45 HKT/SGT
|
|
|
GIC Invests US$100M in Ascletis Pharma (1672. HK): Anchoring Long-Term Capital in China's Core Innovative Drug Assets
Feb 6, 2026 17:45 HKT/SGT
|
|
|
GIC Private Limited initiated a stake in Ascletis Pharma (01672) by 64,128,000 shares at a price of HKD 12.18 per share
Feb 6, 2026 17:01 HKT/SGT
|
|
|
歌禮製藥-B（01672）獲新加坡政府投資公司首次入股 涉資約1億美元
Feb 6, 2026 16:56 HKT/SGT
|
|
|
歌礼制药-B（01672）获新加坡政府投资公司首次入股 涉资约1亿美元
Feb 6, 2026 16:50 HKT/SGT
|
|
|
COSMOPlat Introduces Full-Stack AI to Hong Kong for Trillion-Dollar Industrial Digitalization
Feb 6, 2026 16:34 HKT/SGT
|
|
|
トヨタ、役員人事を発表
Feb 6, 2026 16:00: JST
|
|
|
牧原股份港股上市：全球生豬养殖龍頭 價值成長兼具
Feb 6, 2026 15:08 HKT/SGT
|
|
|
牧原股份港股上市：全球生猪养殖龙头 价值成长兼具
Feb 6, 2026 15:01 HKT/SGT
|
|
|
優異供應鏈賦能與國際化佈局雙輪驅動 綠茶開啟高質量成長新篇章
Feb 6, 2026 14:47 HKT/SGT
|
|
|
优异供应链赋能与国际化布局双轮驱动 绿茶开启高质量成长新篇章
Feb 6, 2026 14:33 HKT/SGT
|
|
|
Everest Medicines Announces China NMPA Approval of VELSIPITY(R) for Adults with Moderately to Severely Active Ulcerative Colitis
Feb 6, 2026 14:17 HKT/SGT
|
|
|
雲頂新耀維適平(R)獲中國國家藥品監督管理局批准上市 為中重度潰瘍性結腸炎治療提供新選擇
Feb 6, 2026 14:11 HKT/SGT
|
|
|
云顶新耀维适平(R)获中国国家药品监督管理局批准上市 为中重度溃疡性结肠炎治疗提供新选择
Feb 6, 2026 14:03 HKT/SGT
|
|
|
Spritzer Celebrates Continued Excellence with Dual Recognition at Putra Brand Awards 2025 and Superior Taste Award 2025
Feb 6, 2026 13:13 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
